Myriad Genetics' Stock Drops After Study Shows Niraparib May Not Need CDx

Oct 10, 2016

NEW YORK (GenomeWeb) – Following publication of a landmark study involving Tesaro's PARP inhibitor niraparib and Myriad Genetics' myChoice HRD test, Myriad's stock tumbled around 12 percent in Monday afternoon trading.

This past weekend, researchers led by Mansoor Mirza of Copenhagen University Hospital in Denmark presented data from the NOVA trial at a European oncology conference, which compared Tesaro's PARP inhibitor niraparib against placebo in 553 patients with recurrent ovarian cancer who had responded to platinum-based chemotherapy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Featured White Papers

Discovering Neuronal Cell Types

How to Use CrownBio's Integrated Oncology Portfolio for Target Identification and Mechanism of Action Elucidation

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Jul

24

Featured Webinar

Identifying Inherited Risk Factors of Pancreatic Cancer Using Targeted Sequencing in a Large Cohort

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Aug

09

Featured Webinar

Analytical Utility of Mass-Spec Liquid Biopsy for NSCLC and Melanoma Samples

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.

Aug

15

Featured Webinar

The Cancer Avatar Project: Analyzing ctDNA to Monitor Treatment Response

This webinar will discuss the Cancer Avatar Project at the California Pacific Medical Center Research Institute (CPMCRI) and the efforts to overcome complexity of tumor profiling using the Accel-Amplicon sequencing workflow from Swift Biosciences.

Aug

27

Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Main menu